Veradigm (MDRX) has just put fresh numbers on the table for FY 2024, with trailing 12 month revenue of US$594.4 million and a reported loss of US$291.5 million, alongside basic EPS of US$2.7 in the red. This sets a clear backdrop of revenue scale paired with negative earnings. The company has seen trailing revenue hold in a tight band between US$588.0 million and US$625.9 million over recent periods, while net income swung from a profit of US$49.2 million to a loss of US$291.5 million. This underlines how earnings have been much more volatile than the top line. For investors, that combination of steady revenue and loss making EPS keeps the spotlight firmly on when margins can rebuild and how durable any improvement might be.

See our full analysis for Veradigm.

With the headline results set, the next step is to test these margin and growth trends against the main stories circulating around Veradigm to see which narratives hold up and which ones the latest numbers start to challenge.

Margins Under Pressure With US$291.5 Million Loss

• Over the last 12 months, Veradigm generated US$594.4 million in revenue while reporting a net loss of US$291.5 million and basic EPS of US$2.70 in the red, which means the business is currently running with negative margins despite relatively steady revenue.
• What stands out for the bullish view that talks about a diversified healthcare data and workflow platform is how that revenue base has moved only modestly, with trailing revenue growth of about 2.5% per year, so the current loss profile sits uncomfortably against a business story that leans on broad product reach and long operating history.
  • Supporters who focus on multiple revenue pillars across providers, payers and life sciences need this US$594.4 million of revenue to convert more cleanly to profit than the loss of US$291.5 million suggests.
  • The long track record since 1986 and broad EHR and analytics offering are consistent with scale, but the recent swing from a trailing profit of US$49.2 million to a loss of US$291.5 million shows that scale alone has not kept earnings stable.

Slow 2.5% Revenue Growth Versus Earnings Turnaround Story

• Trailing revenue growth of about 2.5% per year sits alongside forecasts that earnings could grow at 61.5% per year and that the company is expected to become profitable within three years, so the key tension is between modest top line growth and a rapid earnings recovery narrative.
• Bulls often highlight that Veradigm sits in long term themes like healthcare digitization and real world data, yet the 2.5% revenue growth and current loss of US$291.5 million mean investors have to weigh those sector tailwinds against the actual pace of reported progress.
  • The bullish idea that embedded EHR and analytics tools support durable demand is not directly reflected in the recent earnings path, given EPS moved from a trailing profit of US$0.46 to a loss of US$2.70.
  • At the same time, the forecast return to profitability within three years and projected 61.5% yearly earnings growth, if delivered, would line up more closely with that bullish story than the current trailing figures do.

To see how other investors are connecting these mixed growth and margin signals to their long term stories on the stock, See what the community is saying about Veradigm.

DCF Fair Value Of US$7.61 Versus US$4.90 Price

• With the stock trading at US$4.90 against a DCF fair value of US$7.61 and a P/S of 1.4x versus 2.3x for both the US Healthcare Services industry and peers, Veradigm is currently priced at a discount on both cash flow based and sales based references.
• Critics who focus on the business being unprofitable and growing revenue more slowly than the wider US market at 11.8% per year can point to the US$291.5 million loss as support for caution, even though the roughly 35.6% gap to DCF fair value and lower P/S multiple suggest the market already prices in a fair amount of that risk.
  • The modest 2.5% revenue growth rate compared with the 11.8% benchmark for the broader market reinforces the concern that top line momentum has not yet caught up with the more optimistic earnings forecasts.
  • On the other hand, the expectation of a return to profitability within three years and 61.5% yearly earnings growth is a direct counterpoint to the bearish focus on current losses, especially when combined with the lower valuation multiples.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Veradigm's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Given the mixed tone of the latest figures and forecasts, now is a good time to look through the numbers yourself and stress test each narrative. To see what the current optimism is rooted in and decide whether it matches your own view, start with the 2 key rewards.

See What Else Is Out There

Veradigm is working with modest 2.5% revenue growth, a US$291.5 million loss and volatile earnings, which raises questions about stability and consistency.

If you want ideas where the focus is more on steady fundamentals than on a turnaround story, start comparing opportunities using the 64 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.